Apogee Therapeutics (APGE) Free Cash Flow (2022 - 2026)
Apogee Therapeutics (APGE) reported Free Cash Flow of -$55.6 million for Q1 2026, down 14.09% year-over-year from -$64.7 million in Q1 2025, and up 11.39% quarter-over-quarter from -$62.7 million in Q4 2025.
Apogee Therapeutics (APGE) Free Cash Flow (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Free Cash Flow data on file, last reported at -$55.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$55.6 million, down 14.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 26.67% YoY), and the FY2025 annual result was -$232.6 million, down 34.97% from the prior year.
- Free Cash Flow improved to -$55.6 million in Q1 2026 per APGE's latest filing, from -$62.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$9.2 million in Q4 2022 and troughed at -$67.7 million in Q4 2024.
- A 5-year average of -$38.9 million and a median of -$37.6 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 223.8% in 2023, then advanced 7.39% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$9.2 million in 2022, then plunged by 223.8% to -$29.8 million in 2023, then slumped by 127.58% to -$67.7 million in 2024, then rose by 7.39% to -$62.7 million in 2025, then rose by 11.39% to -$55.6 million in 2026.
- Business Quant data shows APGE's Free Cash Flow at -$55.6 million in Q1 2026, -$62.7 million in Q4 2025, and -$54.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | -55.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.57 Mn |
| Mar 31, 2026 | -55.57 Mn |
| Dec 31, 2025 | -62.71 Mn |
| Dec 31, 2025 | -62.71 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Jun 30, 2025 | -66.89 Mn |
| Jun 30, 2025 | -66.89 Mn |
| Mar 31, 2025 | -48.71 Mn |
| Mar 31, 2025 | -48.71 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Sep 30, 2024 | -43.28 Mn |
| Sep 30, 2024 | -43.28 Mn |
| Jun 30, 2024 | -29.35 Mn |
| Jun 30, 2024 | -29.35 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Dec 31, 2023 | -29.75 Mn |
| Dec 31, 2023 | -29.75 Mn |